Legal Representation
Attorney
Thad Chaloemtiarana
USPTO Deadlines
Application History
48 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 3, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 3, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 9, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Dec 8, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Dec 8, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 30, 2022 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Nov 30, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 21, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 19, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| May 19, 2022 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| May 19, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 23, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 19, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 19, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 19, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 19, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 17, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 17, 2021 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 17, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 18, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 17, 2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Nov 17, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 17, 2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Nov 16, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 16, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 16, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 11, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jun 11, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jun 11, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jun 2, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Apr 7, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Apr 7, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Mar 18, 2020 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Mar 4, 2020 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 12, 2020 | RCCK | S | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | Loading... |
| Feb 11, 2020 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 24, 2019 | GNS3 | O | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | Loading... |
| Jul 24, 2019 | GNSL | S | LETTER OF SUSPENSION E-MAILED | Loading... |
| Jul 24, 2019 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jun 17, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 17, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 17, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 21, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 21, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 21, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 16, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 15, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 25, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and therapeutic preparations for the treatment of aging-related disease including sarcopenia, presbyopia, cancers, cardiovascular disorders, and osteoarthritis; biologics and biotherapeutics for the treatment of aging-related disease including sarcopenia, presbyopia, cancers, cardiovascular disorders, and osteoarthritis
Classification
International Classes
005